Valeant Pharmaceuticals International Inc is in talks to buy Egyptian drugmaker Amoun Pharmaceutical Co to expand its veterinary and human medicines portfolio, Bloomberg reported, citing people familiar with the matter. A sale could value Amoun at $700 million to $800 million, Bloomberg reported. Valeant was not immediately available for comment. Should Amoun fail to find a buyer, it may consider an initial public offering in London, the report said. Amoun could not be immediately reached for comment. http://english.ahram.org.eg/News/130746.aspx